Long-lived fusions of human haematological tumour cells and B-lymphoblastoid cells induce tumour antigen-specific cytotoxic T-cell responses in vitro

Immunobiology

Volumn 217, Issue 7, 2012, Pages 719-729

  Mohamed, Yehia S ^a,b   Dunnion, Debbie ^a   Teobald, Iryna ^a   Walewska, Renata ^a,c   Browning, Michael J ^a,c  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b AL AZHAR UNIVERSITY   (Egypt)

^c LEICESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

Cancer; Fusion; Hybrid; Immunotherapy; Vaccine

Indexed keywords

B7 ANTIGEN; CD86 ANTIGEN; HLA A2 ANTIGEN; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; MELANOMA ANTIGEN 1; NY ESO 1 ANTIGEN; SURVIVIN; TUMOR ANTIGEN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; CELL DIVISION; CELL FUSION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; HYBRID CELL; IMMUNOGENICITY; IN VITRO STUDY; LEUKEMIA CELL; LYMPHOBLASTOID CELL; LYMPHOCYTE ACTIVATION; MULTIPLE MYELOMA; MYELOMA CELL; PERIPHERAL LYMPHOCYTE; PRE B LYMPHOCYTE; PRIORITY JOURNAL;

ANTIGENS, CD80; ANTIGENS, CD86; ANTIGENS, NEOPLASM; CELL FUSION; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; GENE EXPRESSION; HEMATOLOGIC NEOPLASMS; HISTOCOMPATIBILITY ANTIGENS CLASS II; HLA-A2 ANTIGEN; HUMANS; HYBRID CELLS; IMMUNOTHERAPY; INHIBITOR OF APOPTOSIS PROTEINS; LYMPHOCYTE ACTIVATION; NEOPLASM PROTEINS; NEOPLASTIC CELLS, CIRCULATING; T-LYMPHOCYTES, CYTOTOXIC; TIME FACTORS;

EID: 84861198653     PISSN: 01712985     EISSN: 18783279     Source Type: Journal    
DOI: 10.1016/j.imbio.2011.12.001     Document Type: Article

References (36)

1. Almand B., Resser J.R., Lindman B., Nadaf S., Clark J.I., Kwon E.D., Carbone D.P., Gabrilovich D.I. Clinical significance of defective dendritic cell differentiation in cancer. Clin. Cancer Res. 2000, 6(5):1755-1766.
2. Avigan D., Vasir B., Gong J., Borges V., Wu Z., Uhl L., Atkins M., et al. Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses. Clin. Cancer Res. 2004, 10(14):4699-4708.
3. Avigan D.E., Vasir B., George D.J., Oh W.K., Atkins M.B., McDermott D.F., Kantoff P.W., et al. Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma. J. Immunother. 2007, 30(7):749-761.
4. Brossart P., Schneider A., Dill P., Schammann T., GRunebach F., Wirths S., Kanz L., et al. The epithelial tumor antigen MUC1 is expressed in haematological malignancies and is recognized by MUC1-specific cytotoxic T-lymphocytes. Cancer Res. 2001, 61(18):6846-6850.
5. Cywinski A.L., Dunnion D.J., Teobald I., Tucker V.C., Browning M.J. Hybrid cells formed by fusion of Epstein-Barr virus-associated B-lymphoblastoid cells and either marrow-derived or solid tumour-derived cell lines display different co-stimulatory phenotypes and abilities to activate T-cell responses in vitro. Tissue Antigens 2006, 68(2):115-126.
6. Dunnion D.J., Cywinski A.L., Tucker V.C., Murray A.K., Rickinson A.B., Coulie P., Browning M.J. Human antigen-presenting cell/tumour cell hybrids stimulate strong allogeneic responses and present tumour-associated antigens to cytotoxic T cells in vitro. Immunology 1999, 98(4):541-550.
7. Edwards P.A., Smith C.M., Neville A.M., O'Hare M.J. A human-hybridoma system based on a fast growing mutant of the ARH-77 plasma cell leukaemia-derived line. Eur. J. Immunol. 1982, 12(8):641-648.
8. Galea-Lauri J., Darling D., Mufti G., Harrison P., Farzaneh F. Eliciting cytotoxic T lymphocytes against acute myeloid leukaemia-derived antigens: evaluation of dendritic cell-leukaemia cell hybrids and other antigen-loading strategies for dendritic cell-based vaccination. Cancer Immunol. Immunother. 2002, 51(6):299-310.
9. Gong J., Chen D., Kashiwaba M., Kufe D. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat. Med. 1997, 3(5):558-561.
10. Gong J., Koido S., Kato Y., Tanaka Y., Chen D., Jonas A., Galinsky I., et al. Induction of anti-leukaemic cytotoxic T lymphocytes by fusion of patient-derived dendritic cells with autologous myeloblasts. Leuk. Res. 2004, 28(12):1303-1312.
11. Greiner J., Ringhoffer M., Taniguchi M., Li L., Schmitt A., Shiku H., Dohner H., Schmitt M. mRNA expression of leukaemia-associated antigens in patients with acute myeloid leukaemia for the development of specific immunotherapies. Int. J. Cancer 2004, 108(5):704-711.
12. Haque T., Wilkie G.M., Jones M.M., Higgins C.D., Urquhart G., Wingate P., Burns D., et al. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood 2007, 110(4):1123-1131.
13. Heslop H.E., Slobold K.S., Pule M.A., Hale G.A., Rousseau A., Smith C.A., Bollard C.M., et al. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 2010, 115(5):925-935.
14. Hosken N.A., Bevan M.J. Defective presentation of endogenous antigen by a cell line expressing class I molecules. Science 1990, 248(4953):367-370.
15. Klammer M., Waterfall M., Samuel K., Turner M.L., Roddie P.H. Fusion hybrids of dendritic cells and autologous myeloid blasts as a potential cellular vaccine for acute myeloid leukaemia. Br. J. Haematol. 2005, 129(3):340-349.
16. Marjit E., Wafelamn A., van der Hoorn M., van Bergen C., Bongaerts R., van Luxemburg-Heijs S., van den Muijsenberg J., et al. Phase I/II feasibility study evaluating the generation of leukemia-reactive cytotoxic T lymphocyte lines for treatment of patients with relapsed leukaemia after allogeneic stem cell transplantation. Haematologica 2007, 92(1):72-80.
17. Marten A., Renoth S., Heinicke T., Albers P., Pauli A., Mey U., Caspari R., et al. Allogeneic dendritic cells fused with tumor cells: preclinical results and outcome of a clinical phase I/II trial in patients with metastatic renal cell carcinoma. Hum. Gene Ther. 2003, 14(5):483-494.
18. Meehan K.R., Wu J., Webber S.M., Barber A., Szczepiorkowski Z.M., Sentman C. Development of a clinical model for ex vivo expansion of multiple populations of effector cells for adoptive cellular therapy. Cytotherapy 2008, 10(1):30-37.
19. Nanni P., Nicolettis G., de Giovanni C., Landuzzi L., Di Carlo E., Cavallo F., Pupa S.M., et al. Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic mice. J. Exp. Med. 2001, 194(9):1195-1205.
20. Raje N., Hideshima T., Davies F.E., Chauhan D., Treon S.P., Young G., Tai Y.T., et al. Tumor cell/dendritic cell fusions as a vaccination strategy for multiple myeloma. Br. J. Haematol. 2004, 125(3):343-352.
21. Rapoport A.P., Stadmauer E.A., Aqui N., Badros A., Cotte J., Chrisley L., Veloso E., et al. Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer. Nat. Med. 2005, 11(11):1230-1237.
22. Rosenblatt J., Vasir B., Uhl L., Blotta S., Macnamara C., Somaiya P., Wu Z., et al. Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma. Blood 2011, 117(2):393-402.
23. Schmidt S.M., Schag K., Muller M.R., Weck M.M., Appel S., Kanz L., Grunebach F., Brossart P. Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells. Blood 2003, 102(2):571-576.
24. Siders W.M., Vergilis K.L., Johnson C., Shields J., Kaplan J.M. Induction of specific antitumor immunity in the mouse with the electrofusion product of tumor cells and dendritic cells. Mol. Ther. 2003, 7(4):498-505.
25. Sugita Y., Wada H., Fujita S., Nakata T., Sato S., Noguchi Y., Jungbluth A.A., et al. NY-ESO-1 expression and immunogenicity in malignant and benign breast tumors. Cancer Res. 2004, 64(6):2199-2204.
26. Suzuki T., Fukuhara T., Tanaka M., Nakamura A., Akiyama K., Sakakibara T., Koinuma D., et al. Vaccination of dendritic cells loaded with interleukin-12-secreting cancer cells augments in vivo antitumor immunity: characteristics of syngeneic and allogeneic antigen-presenting cell cancer hybrid cells. Clin. Cancer Res. 2005, 11(1):58-66.
27. Tanaka Y., Koido S., Chen D., Gendler S.J., Kufe D., Gong J. Vaccination with allogeneic dendritic cells fused to carcinoma cells induces antitumor immunity in MUC1 transgenic mice. Clin. Immunol. 2001, 101(2):192-200.
28. Trefzer U., Herberth G., Wohlan K., Milling A., Thiemann M., Sherev T., Sparbier K., et al. Vaccination with hybrids of tumor and dendritic cells induces tumor-specific T-cell and clinical responses in melanoma stage III and IV patients. Int. J. Cancer 2004, 110(5):730-740.
29. Turin I., Pedrazzoli P., Tullio C., Montini E., La Grotteria M.C., Schiavo R., Perotti C., et al. GMP production of anti-tumor cytotoxic T-cell lines for adoptive T-cell therapy in patients with solid neoplasia. Cytotherapy 2007, 9(5):499-507.
30. Van Baren N., Brasseur F., Godelaine D., Hames G., Ferrant A., Lehmann F., Andre M., et al. Genes encoding tumor-specific antigens are expressed in human myeloma cells. Blood 1999, 94(4):1156-1164.
31. Vasir B., Borges V., Wu Z., Grosman D., Rosenblatt J., Irie M., Anderson K., et al. Fusion of dendritic cells with multiple myeloma cells results in maturation and enhanced antigen presentation. Br. J. Haematol. 2005, 129(5):687-700.
32. Walewska R., Teobald I., Dunnion D., Abdulmajed H., Aldred M., Sadler J., Chapman C., Browning M. Preclinical development of hybrid cell vaccines for multiple myeloma. Eur. J. Haematol. 2007, 78(1):11-20.
33. Wang J., Saffold S., Cao X., Krauss J., Chen W. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines. J. Immunol. 1998, 161(10):5516-5524.
34. Warren E.H., Fujii N., Akatsuka Y., Chaney C.N., Mito J.K., Loeb K.R., Gooley T.A., et al. Therapy of relapsed leukaemia after allogeneic hematopoietic cell transplantation with T cells specific for minor histocompatibility antigens. Blood 2010, 115(19):3869-3878.
35. Xia J., Tanaka Y., Koido S., Liu C., Mukherjee P., Gendler S.J., Gong J. Prevention of spontaneous breast carcinoma by prophylactic vaccination with dendritic/tumor fusion cells. J. Immunol. 2003, 170(4):1980-1986.
36. Yasuda T., Kamigaki T., Kawasaki K., Nakamura T., Yamamoto M., Kanemitsu K., Takase S., et al. Superior anti-tumor protection and therapeutic efficacy of vaccination with allogeneic and semiallogeneic dendritic cell/tumor cell fusion hybrids for murine colon adenocarcinoma. Cancer Immunol. Immunother. 2007, 56(7):1025-1036.